BT Group Transforms its Business Approach with a Cloud Core Network from Juniper Networks to Enable New Services at Exceptional Scale and Quality Globally
Juniper Networks (NYSE:JNPR), a leader in secure, AI-driven networks, today announced it is supporting BT Group’s ongoing transformation journey towards a highly scalable, automated and robust cloud core infrastructure for business and consumer customers. BT Network Cloud supports diverse network applications across broadband, fixed, mobile and other mission-critical services on a single platform, using Juniper Networks’ high-performance cloud-native solutions and professional services.
With this strategic deployment, BT Network Cloud has now scaled to accommodate multiple key network-centric applications, such as mobile voice and data, broadband authentication and IP voice calls for tens of millions of customers without extra overhead costs. An innovative global technology footprint from Juniper, including infrastructure consolidation and virtualization, along with improved hardware density and power efficiency, reduces space and power requirements in support of a more sustainable infrastructure.
BT Simplifies and Improves Service Quality with Agile Network Cloud
BT Network Cloud enables applications that underpin BT Group's U.K. consumer and business network services. Juniper’s high-performance, high-availability fabric for BT Network Cloud provides extreme robustness and high performance for BT Group’s core applications across a widely distributed user base deployed at multiple locations across the U.K. Moving from dedicated compute platforms for each application to a shared infrastructure conserves and optimizes resources leading to better resource utilization and significantly lower environmental impact.
The provider’s network cloud optimizes service quality and streamlines operational deployment and management of core applications, which enables innovation and agility in delivering new services to market such as enhanced 5G services.
5G Roll Out and Scale to Meet Digital Demand
The introduction of 5G created a unique opportunity for BT Group to transform its core network to ensure it was well-positioned to offer a dynamic range of new services to customers at unprecedented scale. BT Group chose to build a network cloud to provide a common shared platform for core applications, which operate its broadband, fixed and mobile services. BT Group has migrated tens of millions of mobile subscribers and successfully deployed all its mobile application infrastructure on its network cloud.
The goal of the multiyear journey at BT Group was to deploy a state-of-the-art container-based fixed, broadband and mobile core that will boost business agility, operational efficiency, sustainability and meet security compliance.
News Highlights:
-BT uses Juniper for open, software-defined networking (SDN), switching and firewall solutions for its network cloud. The service provider uses Juniper’s SDN platform to automate the creation and management of its OpenStack-based telco cloud. The platform provides hybrid SDN orchestration and centralized control of virtual switching, routing and security. BT is running cloud-native containerized applications and optimizing costs using OpenStack.
-Juniper QFX Series Switches provide the high-performance, high-availability fabric needed to support the BT Network Cloud which has rapidly become the largest container-based cloud infrastructure in the world, and is still growing.
-BT’s cloud-native platform is deployed at multiple locations across the U.K. to form a distributed architecture designed to scale seamlessly alongside demand and to provide services closer to the end user than with traditional, more centralized deployments.
-Juniper collaborated with BT to deliver high-performance, high-availability fabric for BT Network Cloud. BT’s data centers contain over 1,000 Juniper QFX Series Switches and 2,000 Juniper vRouters. The switches connect all mission-critical application servers to the core network. The SDN platform is deployed on the servers to provide virtualized routing capability to connect workloads across BT’s network securely.
-Juniper vSRX Virtual Firewalls protect and secure the data center traffic. vSRX provides a network address translation capability which was not possible for one of BT’s application providers to deliver in software.
-BT Group selected Juniper for its engineering excellence and ability to provide an end-to-end network solution including hardware, software and tools that can integrate reliably with the complete cloud stack.
-By leveraging Juniper’s professional services, BT has successfully completed the project on time and ensured that the challenging service level, availability and performance targets of BT’s applications are met.
Supporting Quotes:
“Telecoms services have become central to business and consumer lives and as the U.K.’s national network provider, BT Group has a particular responsibility to lead from the front to deliver the cloud-native, sustainable digital services of the future. Our work with partners such as Juniper is helping to ensure that our critical infrastructure, network and services are agile, secure and resilient for the long term. Our millions of customers can remain confident in the experience-led integrity of the everyday and exceptional digital services on which they rely.”
- Howard Watson, Chief Security and Networks Officer, BT Group
“We are delighted that Juniper’s cloud-native networking solutions and comprehensive professional services were selected as the cornerstone of the BT Network Cloud. BT can respond to the demands of the next chapter of digital transformation at scale whilst leveraging the power of the network to enable new digital services for BT’s customers, fully supported by a cloud-native architecture enabling security, automation, scale and agility.”
- Raj Yavatkar, Chief Technology Officer, Juniper Networks
Additional Resources
BT: Success Story
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719046766/en/
Contact information
Media Relations:
Pelin Murphy
Juniper Networks
pelin@juniper.net
+44 (0) 1372 385 686
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom